GlassScriptPhysician profile
Frank Anderson
NPI 1497149884
$1,889.28
in general payments reported to CMS, 2019-2025
20 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.67 · 2020: $428 · 2021: $349 · 2022: $283 · 2023: $215 · 2024: $222 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.71 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $261.27 | 2021-2025 | Airsupra, Evusheld, Breztri |
| Abbvie INC. | $258.05 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $197.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $187.52 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $86.27 | 2024-2025 | Cologuard Collection Kit |
| Insulet Corporation | $47.74 | 2025 | Omnipod |
| Pfizer INC. | $38.90 | 2023-2024 | |
| Abbott Laboratories | $37.95 | 2021-2024 | |
| Genentech USA, INC. | $35.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.46 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.54 | 2020 | |
| Seqirus USA INC | $26.35 | 2025 | Flucelvax, Fluad |
| Dexcom, INC. | $20.74 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $19.62 | 2023 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $18.50 | 2023 | Rebyota |
| Eisai INC. | $16.29 | 2020 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.